Skip to main content
Peptide Intel Hub laboratory research video
Peptide Intel Hub

Protocols · Cognitive

PE-22-28: literature-reported ranges

PE-22-28 is a shortened analogue of spadin, studied as a fast-acting antidepressant candidate via TREK-1 potassium channel blockade. All published work is rodent; no human study exists.

Read this first

Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.

Compound at a glance

Class
Spadin analogue, TREK-1 channel blocker
Reported half-life
Short; rodent designs use daily administration
Routes used in the literature
Intravenous, intraperitoneal and intranasal in mouse studies
Also written as

What the published studies reported

Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.

Mouse antidepressant-behaviour models

Reported quantity
100 µg/kg
Frequency
Once daily
Study duration
4 days in the classic design; up to 3 weeks in longer arms

Behavioural effects were reported after four days, which is the basis of the 'fast-acting' framing.

Rodent stroke and neurogenesis models

Reported quantity
Around 100 µg/kg intranasally or intravenously
Frequency
Once daily
Study duration
3–7 days post-insult

Hippocampal neurogenesis markers are the usual secondary readout.

Dosage chart

These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.

PE-22-28 · 10 mg Vial

PE-22-28 is dosed at 50 mcg–200 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Reconstitute
Add 3.0 mL bacteriostatic water → ~ 3.33 mg/mL concentration.
Typical daily range
50–200 µg once daily (gradual titration over 8–16 weeks).
Easy measuring
At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 µg on a U-100 insulin syringe.
Storage
Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); protect from light.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

WeekDaily Dose (µg)Units (per injection) (mL)
Weeks 1–250 µg1.5 units (0.015 mL)
Weeks 3–4100 µg3 units (0.03 mL)
Weeks 5–8100 µg3 units (0.03 mL)
Weeks 9–12 (Optional)150 µg4.5 units (0.045 mL)
Weeks 13–16 (Optional)200 µg6 units (0.06 mL)
Source chart on peptidedosages.com

Reconstitution maths

A 5 mg vial in 2 mL of bacteriostatic water gives 2.5 mg/mL.

Open the reconstitution calculator

How to read these figures

  • TREK-1 blockade is a mechanism with no approved human precedent.
  • Rodent behavioural despair models translate poorly to human mood outcomes.
  • There is no human safety data whatsoever.

Sources and citations

These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.

  1. [1]
    Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity

    Djillani A, Pietri M, Moreno S, Heurteaux C, Mazella J, Borsotto M. · Front Pharmacol · 2017 · PMCID PMC5601071

    Mice were given intravenous or intraperitoneal injections of the shortened spadin analog PE-22-28 at doses of approximately 1-2 mg/kg to test antidepressant-like activity in forced swim and other behavioral tests.

    View the record

Search the databases yourself

Read the PE-22-28 research brief

Other cognitive compounds

All research protocols

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.

Share
© 2026 Peptide Intel Hub · Marbella · Educational research reference · For in-vitro research use only
Independent publication — we sell nothing. Supplier disclosure

Peptide Intel Hub is an independent educational publication. We are not affiliated with, owned by, or the same company as Regena Peptides and Regena.app (regena-peptides.com / regena.app). We do not sell, supply, ship or take payment for any compound. Because readers regularly ask where compounds discussed in published studies can be sourced for laboratory work, we list Regena Peptides and Regena.app as suppliers we have verified and trust — every batch is released with a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity). Outbound links are marked nofollow/sponsored and are provided to help readers, not to sell.